Exceptional molecular testing for bladder cancer

The Decipher® Bladder Genomic Classifier reveals the molecular subtype of a patient’s bladder cancer to help inform key treatment decisions.

  • Screening
  • Diagnosis
  • Prognosis/​treatment selection
  • Recurrence monitoring

Decipher Bladder


Decipher Bladder offers insights into the molecular subtype of a bladder tumor

An older man holding a smiling baby.

The Decipher Bladder Genomic Classifier is a novel molecular subtyping tool that helps physicians navigate complex and potentially life-changing treatment decisions for patients with bladder cancer. The Decipher Bladder test uses whole-transcriptome analysis and machine-learning algorithms to classify bladder tumors into five molecular subtypes, each with distinct biological characteristics. Armed with this information, physicians can be better prepared to guide bladder cancer treatment decisions for their patients.

An older man holding a smiling baby.


Identify risk and inform treatment decisions for bladder cancer

Decipher Bladder is a genomic test that assesses the molecular profile of 219 genes in bladder tumor specimens. The test is designed for use in patients following bladder cancer diagnosis who face questions of treatment intensity. The test results are reported as either Luminal or Non-Luminal (Infiltrated, Basal, Basal Claudin-Low or Neuroendocrine-like), with each molecular subtype having a distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy (NAC).

Decipher Bladder logo


Lower risk of cancer upstaging; less likely to benefit from NAC


Higher risk of cancer upstaging; more likely to benefit from NAC

Clinical data for Decipher Bladder

The Decipher Bladder Genomic Classifier is supported by multiple peer-reviewed clinical studies demonstrating the test’s ability to identify which patients with bladder cancer have a higher risk of upstaging to non-organ confined disease (i.e., disease that has spread outside the bladder wall and/or to nodes in the pelvis) at surgery and/or may be more likely to benefit from neoadjuvant chemotherapy. The test can also be used to identify neuroendocrine-like and immune-infiltrated subtypes, which may have implications for patients being considered for clinical trials of novel therapies.


people are currently indicated for the Decipher Bladder test.1


patients from leading cancer centers across North America and Europe were included in validation studies for the Decipher Bladder test.2


In European Urology: “Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors”

In Urologic Oncology: “Validation of a Neuroendocrine-like Classifier Confirms Poor Outcomes in Patients with Bladder Cancer Treated with Cisplatin-based Neoadjuvant Chemotherapy”

Serving patients across the US

The Decipher Bladder Genomic Classifier is available to patients and their physicians in the US. All testing is performed in Veracyte’s centralized laboratories. The test is covered by Medicare.

Featured events

Learn more about the Decipher Bladder test by meeting with us at upcoming events.

A physician showing information to an older patient on a tablet.
An older patient and physician discuss medical information together.

Learn about the Decipher Bladder cancer test


  1. Company estimate based on CT1-CT4A.

  2. Decipher Bladder publications

The Decipher Bladder Genomic Classifier is available in the US as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA.

This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.